Monitoring the intrahepatic immune responses in chronic HBV patients after long-term treatment with tenofovir

Monitoring the intrahepatic immune responses in chronic HBV patients after long-term treatment with tenofovir - HBV-FNAB FU

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON41768

Enrollment

Registered

2015-01-05

Start date

2015-06-01

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis B

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: * Chronic HBV patients who were included in the Tenofovir-FNAB study, and are currently still under treatment with tenofovir or became HBsAg-negative (HBsAg loss) in the meantime * Signed informed consent

Exclusion criteria

Exclusion criteria: * (Re-) infection with HIV, hepatitis B or C after the Tenofovir-FNAB study * Decompensatedcirrhosis (Child * Pugh Grade B or C) * Ultrasonic or other prove of hepatocellular carcinoma or other carcinoma * Pregnant woman * Any other condition or prescribed medication in which in the opinion of the investigator would make the patient unsuitable for enrollment.

Design outcomes

Primary

Measure	Time frame
Frequency, phenotype and function of intrahepatic and peripheral NK cells	—

Secondary

Measure	Time frame
N.A.	—

Countries

Netherlands

Outcome results